CD25 definition
Examples of CD25 in a sentence
After infection, the cells will be stimulated with anti-CD3 and, two days later, those cells containing a library member (positive for the fluorescent reporter) and inhibited for surface expression of CD25 will be enriched by FACS.
Those that express CD3 will be cultured with anti-CD3 to crosslink the TCR and test for the upregulation of CD25 and production of IL-2 (Appendix A).
Since Cytolin is hypothesized to prevent the lysis of activated CD4+ T cells, the cells will additionally be stained with CD69, CD25, and CD38 to determine if these cellular subsets arc preferentially maintained in cultures which contain Cytolin.
Treg cells in BAL fluid, medLNs and blood were identified by staining with live/dead fixable aqua dead cell stain kit (ThermoScientific) and fluorescently labelled antibodies against CD3 (17A2), CD4 (GK1.5), CD25 (PC61.5), CTLA-4 (UC10-4B9), Foxp3 (FJK-16s) and GITR (YGITR 765).
Tregs are CD4 T cells characterized by high levels of CD25 expression and expression of the FoxP3 transcription factor, and are able to mediate suppression of effector T cell responses through cell-to-cell contact and through secretion of soluble mediators such as IL-10 and TGFβ.
Splenic T cell subsets were determined by staining for CD4 and the transcription factors T-bet (Th1), GATA-3 (Th2), RORγt (Th17) B Naive Effector D and Foxp3 (CD25+ Tregs) (C).
The effect of MDSC administration % within CD4+ T cells 15 60 on spleen cell proliferation was 9 50 S.I. T-bet GATA-3 ROR t + Foxp3 CD25 Control MDSCs determined by culturing splenocytes (n=5 per group) in the presence or absence of CD3/CD28 stimulation (D).
Specifically, ▇▇ et al demonstrated that CD4+ CD25+ Tregs within the tumour inhibited proliferation and activation of anti- tumour CTL and blocked the production of IFNγ.
Oqory assets included as part of the Merger (the “Oqory Assets”) would consist of those presented by Oqory to Vincerx during the course of discussions and negotiations, including, without limitation, the following: STI-3258 – TROP2 ADC; STI-6129 – CD38 ADC; STI-8811 – BCMA ADC; ROR1 ADC; B7-H3 ADC; CD25 ADC; and Next Gen Trop-2 ADC All existing Vincerx Common Stock and options, warrants, and rights to acquire Vincerx Common Stock would remain outstanding following the Merger in accordance with their terms.
The following antibodies were purchased from eBioscience: IFNγ (XMG1.2), IL- 17A (eBio17B7), CD25 (PC61.5), CD3ε (eBio500A2), and RORγ(t)-PE (B2D).